J&J Seeks FDA Approval for OTTAVA Robotic System, Expanding Surgical Automation

Event summary

  • Johnson & Johnson submitted the OTTAVA™ Robotic Surgical System to the FDA for De Novo classification in January 2026.
  • The submission is based on data from an Investigational Device Exemption (IDE) study completed in early 2025 at Memorial Hermann-Texas Medical Center.
  • OTTAVA is designed for multiple procedures in general surgery within the upper abdomen, including gastric bypass and hiatal hernia repair.
  • A second IDE trial for inguinal hernia repair was approved in late 2025.
  • The system integrates Ethicon surgical instrumentation and is intended to connect with Johnson & Johnson’s Polyphonic™ digital ecosystem.

The big picture

Johnson & Johnson’s OTTAVA system represents a significant investment in the growing robotic surgery market, which is projected to reach billions in the coming years. The De Novo pathway suggests a differentiated approach, potentially bypassing some regulatory hurdles but also signaling a degree of novelty that could face scrutiny. The integration with the Polyphonic digital ecosystem hints at a broader strategy to capture data and enhance surgical workflows, but also introduces complexity and dependency on a nascent digital platform.

What we're watching

Regulatory Approval
The FDA's De Novo classification process will be critical; a protracted review could delay commercialization and impact investor expectations.
Market Adoption
The success of OTTAVA will depend on surgeon adoption and integration into existing hospital workflows, potentially requiring significant training and support.
Competitive Landscape
How J&J positions OTTAVA against established robotic surgery platforms like Intuitive Surgical’s da Vinci system will determine its market share and long-term viability.

Related topics

Medical Devices